Amrize Ltd (NYSE: AMRZ) — A Local-Monopoly Rock-and-Cement Core, Diluted by a Goodwill-Heavy Roofing Roll-Up and Priced for Its Own Self-Help to Land

Independent Equity Research Report date: 2026-07-18 · Price reference: ~$49.74 (2026-07-17 close) · CIK 0002035989 · NYSE + SIX Swiss Exchange · FY ends 31 December · Reporting currency USD, U.S. GAAP · Swiss-domiciled (Zug), operational HQ Chicago

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows takes no position and carries no price target; the only opinion is in this clearly-fenced block.

Verdict: HOLD — a genuinely good business at an honest-to-slightly-full price. Accumulate on weakness toward the low-$40s; do not chase here. Not a short. Fair-value zone ≈ $44–54 (≈10–11.5x 2026E adjusted EBITDA of ~$3.25B, ≈19–22x 2026E EPS of ~$2.35–2.55, ~5.5% forward FCF yield). The price you actually want is sub-$44 — roughly where the stock traded in the post-spin flush of August 2025 (~$43.7) — which would put the aggregates/cement core close to a fair standalone multiple and hand you the roofing business for a modest premium to its own goodwill.

Amrize is the crown-jewel North American business Holcim spun out in June 2025: a leading North American cement platform (management calls its Ste. Genevieve, Missouri plant the continent’s largest — an IR claim, not a filed one), an 8.2-billion-ton aggregates reserve base, and a bolted-on Building Envelope roofing franchise (Elevate/Firestone, Malarkey, Duro-Last). The core is a textbook local-monopoly: aggregates and cement are low-value, high-weight products that are uneconomic to ship far, protected by geology, permitting and freight — the most durable moat type in industrials (Greenwald’s cost/geographic advantage). That core earns ~29–33% segment EBITDA margins and real pricing power. The problem is what sits on top of it. Holcim doubled this company’s size in a few years by rolling up roofing at high multiples, and the bill shows up on the balance sheet as $10.75B of goodwill and intangibles (44% of assets) and a blended ROIC of only ~7.6% — below a plausible ~8–9% WACC. So you own a wonderful cash engine whose returns on total invested capital are mediocre because management paid up to assemble the second leg.

The framing is quality-core-diluted, priced-for-execution — closest cousin in our coverage is CRH: a blended materials compounder that trades at ~12x EBITDA and never re-rates to the ~18–20x pure-aggregates multiple of Vulcan/Martin Marietta, because the mix (roofing, ready-mix) structurally caps blended margin and return. At ~$50 / ~12x trailing / ~10x forward EBITDA, AMRZ is not expensive on forward numbers if you believe the 2026 guide (+4–6% revenue, +8–11% EBITDA, 70bps of ASPIRE self-help). But 2025 was a flat-revenue, down-margin, down-EPS year, the residential-roofing leg is in a genuine downcycle, and roughly all the near-term upside rests on (a) synergies management has never before extracted and (b) a rate-cut-driven commercial recovery plus a data-center construction boom. The tape agrees the easy money is done: the stock spiked to $65 on the February capital-return announcement and has round-tripped to ~$50, with sell-side now trimming (Truist → Hold, $48).

Conviction: medium. Bullish flip: ASPIRE demonstrably delivering (BM margins pushing toward the mid-30s%) and ROIC re-accelerating above ~9–10% as the data-center/infrastructure volume wave lands — that turns “fairly valued cyclical” into “quality compounder you underpaid for.” Bearish flip: the residential cycle stays broken into 2027, aggregates/cement pricing traction disappoints (management’s serial “nothing negative to report” is doing a lot of work), and the M&A machine keeps buying growth at returns below cost of capital — at which point ~24x trailing earnings on a 7.6%-ROIC cyclical is simply too much. Tag: the rock is a fortress; you’re paying a full ticket for the whole house, goodwill and all.

📈 Stock Price Action — Five-Year Event Map

Amrize has only traded since its 23 June 2025 spin, so this is a ~13-month, not five-year, map. The arc is a round trip: it listed near $51, flushed to ~$44 in the post-spin index-rebalancing shakeout, ground back to the low-$50s through late 2025, spiked to an all-time high of ~$65 in February 2026 on its first full-year print and a maiden $1B buyback-plus-special-dividend, then faded steadily back to ~$50 — essentially unchanged from where it began, ~24% below its high. 52-week range ~$43.7–65.3; latest ~$49.74; beta ~1.32 with negative alpha (a high-beta, market-driven cyclical that has underperformed the tape it swings with). (Price moves are Fact; attributed drivers are Interpretation.)

Cycle narrative. (1–2) The spin created a temporary, structural seller: Holcim’s European/index shareholders received AMRZ shares they had no mandate to hold, and with no established US following the stock gapped to ~$44 by early August 2025 — the cleanest entry point of its short life. (3) Through autumn the standalone story stabilized as Building Materials posted volume and pricing growth and management delivered on a sub-1.5x leverage promise. (4) The February 2026 full-year print was the defining event: solid Building Materials margin expansion, a data-center-heavy 2026 outlook, and — critically — the first tangible shareholder return (a $1B repurchase authorization plus a special and ordinary dividend paid partly out of Swiss capital-contribution reserves) drove an ~11% single-day jump to an all-time high near $65. (5–6) That proved the top: with the capital-return catalyst banked and residential roofing still soft, the multiple compressed through spring and summer 2026, and the July sell-side downgrades tipped it back to ~$50 — a full round trip to the spin price.

1. Executive Summary

Amrize Ltd is the North American building-materials pure-play that Holcim Ltd distributed to its shareholders on 23 June 2025 in a tax-free, dividend-in-kind spin-off. It is a ~$11.8B-revenue, ~$3.0B-adjusted-EBITDA business organized in two segments: Building Materials (cement, aggregates, ready-mix concrete, asphalt — $8.5B revenue, 72% of the total, ~29% segment EBITDA margin) and Building Envelope (commercial and residential roofing and wall systems — $3.3B revenue, 28%, ~22% margin). It operates the largest cement platform in North America (anchored by the 5.5M-ton Ste. Genevieve, Missouri plant), a deep aggregates reserve position, and a roofing franchise assembled through Holcim-era acquisitions (Firestone Building Products, Malarkey, Duro-Last). CEO and Chairman Jan Jenisch ran Holcim before the spin; the company is Swiss-domiciled but operationally headquartered in Chicago and dual-listed on the NYSE and SIX Swiss Exchange.

The business quality is bimodal. The Building Materials core is genuinely high-quality — aggregates and cement are the archetypal local-monopoly, freight-protected, hard-to-replicate assets that generate durable pricing power and ~30%+ margins. But the Building Envelope leg, while a decent branded oligopoly business, was bought expensively, and the combined entity carries $10.75B of goodwill and intangibles (44% of total assets). The consequence is a blended ROIC of only ~7.6% — respectable for a cyclical but below a plausible cost of capital, and well beneath the mid-teens returns pure-aggregates peers earn. This is the central tension: a wonderful cash engine whose total-capital returns are diluted by the price paid to assemble it.

The near-term numbers do not yet corroborate the growth narrative. Revenue has been essentially flat since 2022 (~$10.7B → $11.8B), and 2025 was a down year — adjusted EBITDA margin fell ~190bps (25.6% → 23.7% on a GAAP basis), net income slipped to $1.185B from $1.274B, and EPS declined to $2.14 from $2.31 — driven by a soft residential-roofing market and mix. Management’s 2026 guide (+4–6% revenue, +8–11% adjusted EBITDA) leans on three planks: (i) the ASPIRE cost/synergy program (70bps of margin expansion targeted in 2026, $250M run-rate by 2028 — synergies never extracted because the company “doubled from $6B to $12B” without integrating), (ii) a rate-cut-driven commercial recovery, and (iii) a data-center construction boom (30+ projects supplied in 2025). The company is investing behind this — capex rising to ~$900M in 2026 with growth capex more than doubling — and bolting on aggregates (PB Materials, West Texas, ~$180M revenue, closing Q1’26).

Financially the company is in good shape post-spin: net debt of ~$3.3B is just ~1.1x EBITDA, interest coverage ~6.8x, cash conversion ~49% of EBITDA (~$1.4–1.5B free cash flow), and management has initiated a balanced capital-return program (a $1B buyback and dividends, the latter partly shielded from Swiss withholding via capital-contribution reserves). The risks that matter are cyclical (construction demand, rates, residential roofing), structural (cement’s carbon/energy exposure, the goodwill-heavy return profile, distributor concentration as QXO/Beacon consolidates roofing distribution), and executional (whether ASPIRE and the growth capex actually lift returns rather than merely defend them). At ~$50 the market is paying ~12x trailing / ~10x forward EBITDA and ~24x trailing earnings — a full-but-not-egregious price that already discounts the guide landing. The valuation section (§10) frames this as embedded expectations rather than a target.

2. Business Overview

Amrize makes and sells the physical materials that go into North American construction, organized into two reportable segments that are strikingly different in economic character.

Building Materials (72% of revenue, ~77% of segment EBITDA; $8,514M revenue, $2,485M segment adjusted EBITDA, 29.2% margin in FY2025). This is the former Holcim North America heavy-materials business — the reason the spin exists. It spans four product lines: cement (18 plants, 143 distribution terminals, 22.4M tons sold in 2025 at a US realized price of ~$169/ton — cement revenue $4,389M), aggregates (crushed stone, sand and gravel from 467 operations and 376 pits/quarries, 118.9M tons sold at ~$16/ton), ready-mix concrete (273 plants), and asphalt (50 operations). Aggregates-and-other-construction-materials revenue ($4,665M) is actually larger than cement revenue, an important fact for valuation (§10) because aggregates is the higher-quality sub-business. The segment sells into infrastructure (highways, bridges, water), non-residential/commercial (warehouses, data centers, manufacturing) and residential construction, and it is not dependent on any single customer — the natural consequence of selling a local, freight-bound product to thousands of contractors and public agencies.

Building Envelope (28% of revenue, ~23% of segment EBITDA; $3,301M revenue, $732M segment adjusted EBITDA, 22.2% margin). This is the roofing-and-wall-systems franchise Holcim assembled by acquisition, operated through 51 facilities and a portfolio of brands: Elevate (formerly Firestone Building Products — commercial single-ply TPO/EPDM membranes plus polyiso insulation), Duro-Last (custom-fabricated commercial PVC roofing systems), Malarkey (residential asphalt shingles — a #4-tier player behind GAF/Owens Corning/CertainTeed), OX Engineered Products (wall sheathing and house wraps), Enverge (spray-foam insulation) and Gaco (liquid-applied coatings, sealants and adhesives). Roughly 70% of Building Envelope volume moves through distributors (Beacon/QXO, SRS, ABC Supply) with the remainder sold direct to contractors; the 10-K notes that segment “revenues are largely attributable to a few large distributors” — a genuine concentration exposure absent from Building Materials, and a live issue now that QXO is consolidating roofing distribution (§8).

How it makes money. Amrize is a price-times-volume industrial: it earns spreads on materials whose cost is dominated by energy, freight and raw inputs (limestone and slag it largely self-supplies in Building Materials; petroleum-derived membranes, asphalt, resins and glass fiber it buys in Building Envelope). There is a meaningful repair-and-remodel annuity underneath the cyclicality — R&R was 43% of total company revenue in 2025 (the only end-market split the 10-K actually discloses; management’s “~50% commercial / ~30% infrastructure / ~20% residential” framing is call commentary, not a filed figure). Revenue is overwhelmingly transactional rather than contracted-recurring, but the R&R share and the non-discretionary nature of re-roofing give the business more demand stability than a pure new-construction play. The company employs ~19,000 people (about a third under collective-bargaining agreements), is domiciled in Zug, Switzerland for tax and legal purposes, and runs operationally out of Chicago.

3. Industry Dynamics

Amrize straddles four industry structures of very different quality — and the blend, not any single one, is what determines the stock’s fair multiple.

Aggregates — the best capital cycle in building materials (structurally excellent). Crushed stone and sand-and-gravel are low-value, high-weight products: at ~$16/ton, freight doubles the delivered cost within ~30–50 miles, so every quarry is effectively a local mini-monopoly protected by geology and — critically — by a permitting regime that makes new competing pits nearly impossible to open near demand. This is the textbook Greenwald geographic/cost-advantage moat, and it shows up as pricing power that rises every year, including through the 2009–10 volume collapse (per our Vulcan and Martin Marietta work). Amrize’s aggregates ASP rose +6.1% on constant-currency, freight-adjusted terms in 2025 on falling volume — the signature of real local pricing power. In Marathon capital-cycle terms this is the favorable phase: scarce supply, rational incumbents, durable high returns. Amrize’s 8.2-billion-ton reserve base (from 376 pits) is a genuinely valuable, hard-to-replicate asset.

Cement — local oligopoly, but structurally inferior to aggregates (mid-quality). US cement is more capital-intensive, more cyclical, and — decisively — import-exposed on the coasts, where Turkish, Mediterranean and Asian clinker set the marginal price through deep-water ports and the Mississippi River. Inland plants are freight-protected; coastal ones are price-takers at the margin. Amrize’s cement realized just +0.3% constant-currency pricing in 2025 despite industry consolidation — a stark contrast to aggregates, and the tell that cement lacks aggregates’ pricing power right now. Layered on top is a carbon overhang: cement calcination is chemically unavoidable CO₂, cement is ~8% of global emissions, and the 10-K explicitly warns that kiln operations “may be disproportionately affected by future regulation of greenhouse gas emissions” and that the company “may not be able to recover” the resulting costs. Canada already runs a carbon-tax/cap-and-trade regime over Amrize’s plants there. Tellingly, Martin Marietta exited US cement in early 2026 (the Quikrete swap), publicly calling it the “most cyclical, lowest-return” asset it owned — a peer’s revealed judgment that cement deserves a lower multiple than rock.

Commercial roofing — branded oligopoly, favorable (good-quality). Single-ply membrane is a rational four-player oligopoly — Carlisle, Holcim/Amrize-Elevate, GAF and Johns Manville — with strikingly stable manufacturer shares (the Greenwald share-stability test passed) and ~70% of demand coming from non-discretionary re-roofing on a 20–25-year replacement cycle across an aging installed base. Specification and warranty lock-in, plus petrochemical-input purchasing scale, make entry uneconomic. Our Carlisle work characterizes this as “a genuine annuity with pricing power” (~27% CCM margins, ~17% ROIC). Amrize’s Elevate/Duro-Last commercial business sits inside this attractive structure — but as the #2–#3 participant against a stronger Carlisle.

Residential shingles & ready-mix — oligopoly-with-cyclicality and no-moat respectively. Residential shingles (GAF/OC/CertainTeed/Malarkey) is a structurally attractive, >80%-replacement-demand oligopoly, but carries storm-driven cyclicality — the 2020–21 re-roof super-cycle is now normalizing (peers’ residential roofing volumes fell ~7% in 2025, mirroring Amrize’s Building Envelope softness). Amrize’s Malarkey is a subordinate #4 player, not a GAF/OC-caliber franchise. Ready-mix concrete, by contrast, is explicitly low-quality: the 10-K itself concedes “lower capital requirements result in fewer barriers to entry” and describes the market as “highly fragmented” with “strong competition.” It is a commodity that exists largely to pull through cement and aggregates volume.

Verdict: a structurally good-to-excellent core (aggregates, commercial roofing) blended with structurally mediocre pieces (cement’s import/carbon exposure, ready-mix’s no-moat commoditization, residential’s cyclicality). The company is neither a pure-aggregates fortress nor a commodity cyclical — it is a weighted average, and that average sits closer to CRH/Heidelberg’s integrated-materials profile than to Vulcan/Martin Marietta’s pure-rock quality.

4. Competitive Position

The aggregates/cement core has a real, nameable moat; the roofing leg has a weaker, contested one; ready-mix has none. Applying Greenwald’s taxonomy segment by segment:

• Aggregates — supply-side cost advantage + geographic demand-captivity (durable). The moat is physics and permitting, not brand or technology. A quarry near demand cannot be economically undercut because a competitor would have to (a) find a deposit within the ~30–50-mile freight radius and (b) permit it against community opposition and environmental review that routinely takes a decade or fails outright. The financial fingerprint is exactly what theory predicts: +6.1% pricing on down volume, ~30%+ segment margins. This is the piece of Amrize that would genuinely deteriorate if the moat vanished — and it will not vanish.

• Cement — scale + inland freight protection, but capped by imports (moderate). Amrize’s 18-plant network and self-supplied limestone confer real scale economies, and inland plants enjoy freight protection analogous to aggregates. But the +0.3% 2025 pricing exposes the ceiling: on the coasts, imported clinker disciplines price, and no amount of domestic scale changes that. Add the carbon-cost asymmetry and cement is a good-not-great business.

• Commercial roofing — brand/warranty switching costs (moderate, contested). Elevate and Duro-Last sell warrantied systems, and the multi-decade warranty plus contractor training/certification creates genuine spec-in and switching costs — a roofer certified on one manufacturer’s system is reluctant to re-train and re-warranty on another. Amrize holds ~300 US patents and thousands of trademarks. But this moat is shared with Carlisle (the category leader), GAF and Johns Manville, and Amrize is not the strongest of them. The distributor-concentration wrinkle (below) is a real vulnerability the aggregates business does not have.

• Ready-mix / asphalt — no moat. Commodity, fragmented, low-barrier by the company’s own admission. Its value is as a volume-pull channel for the moaty inputs, not as a standalone franchise.

The distributor-concentration asymmetry is the most underappreciated competitive fact. Building Materials sells to thousands of contractors and public agencies with no single-customer dependency — pricing power flows to Amrize. Building Envelope’s “revenues are largely attributable to a few large distributors,” and those distributors are consolidating: QXO’s acquisition of Beacon Building Products (and the broader SRS/ABC Supply scale-up) shifts bargaining power toward the channel. On the Q4’25 call, when asked directly about QXO/Beacon pressuring roofing-manufacturer margins, management deflected (“we partner with all of them… we focus on the end customer”). That is the correct thing to say and an incomplete answer — a more concentrated, more aggressive distribution layer is a structural headwind to Building Envelope economics that will play out over years, not quarters.

Verdict: a durable, high-quality moat in the aggregates/cement core; a real-but-weaker, distributor-pressured moat in commercial roofing; and no moat in ready-mix. The blended competitive position is good, not great — decisively better than a commodity cyclical, decisively worse than a pure-aggregates franchise.

5. Growth History and Forward Opportunities

History: growth by acquisition, not organically. The revenue trajectory tells the story plainly — $8.1B (2021) → $10.7B (2022) → $11.7B (2023) → $11.7B (2024) → $11.8B (2025). The step-change from 2021 to 2023 was the Holcim-era roofing roll-up (Firestone Building Products for ~$3.4B in 2021, Malarkey in 2022, Duro-Last for ~$1.29B in 2023) — Jenisch said on the call the company “doubled from $6B to $12B in the past few years.” Since that acquisition wave closed, organic revenue has been flat-to-down: volumes are falling in the core (cement tons 24.4M → 22.4M since 2023; aggregates 128.9M → 118.9M), offset by price. Adjusted EBITDA actually declined in 2025 ($3,181M → $3,007M), margins compressed ~170bps, and EPS fell from $2.31 to $2.14. This is not a company that has recently grown; it is a company that got bigger by buying, then digested through a soft patch.

Forward: three growth planks, each real but unproven in the numbers.

1. ASPIRE self-help (the most controllable). Management’s central near-term lever is a synergy/procurement program targeting 70bps of margin expansion in 2026 and a $250M run-rate benefit by 2028, sourced from >$7B of third-party spend (logistics, raw materials, maintenance/services) that was never optimized because the company “doubled without running the synergy program.” This is genuinely credible — post-merger procurement synergies on a doubled cost base are among the more reliable value levers in industrials — and early Q4’25 Building Materials margin gains (+60bps) suggest it is starting to land. It is the single most important thing to track.

2. Data centers and the commercial recovery (real, but narrative-heavy). Management leans hard on data-center construction — “over 40% of global data center infrastructure investment… in the US through 2030,” 30+ projects supplied in 2025, the Elevate MAX PVC roofing system spec’d into hyperscaler builds. This is a genuine demand tailwind for both cement/aggregates (foundations, surrounding infrastructure) and commercial roofing. But the 10-K quantifies none of it — data centers appear exactly once, qualitatively — so it functions today as a credible thesis rather than a measured revenue line. The broader commercial recovery hinges on rate cuts unlocking warehouse/logistics/manufacturing starts, which management (correctly) argues matters more to its commercial customers than mortgage rates do to housing.

3. Growth capex + bolt-on M&A (funded and underway). Capex is rising to ~$900M in 2026 (from $788M), with growth capex more than doubling — debottlenecking flagship cement plants (the Ste. Genevieve, Missouri expansion management calls North America’s largest, adding ~660k tons; a new Oklahoma greenfield quarry with ~200M tons of reserves for Dallas–Fort Worth; a new Malarkey shingle plant for the Midwest/East by end-2026). On M&A, Amrize is buying aggregates: PB Materials (West Texas, ~$180M revenue, 50 years of reserves, ~30% local share, EPS-accretive, closing Q1’26) with “a strong pipeline… led by aggregates.” Buying aggregates rather than more roofing is the right direction — it adds to the moaty core rather than the goodwill-heavy leg.

Verdict: low-quality recent growth (acquired, now digesting) transitioning to a plausible but unproven forward growth story that rests on self-help execution and a cyclical/secular commercial recovery. The 2026 guide (+4–6% revenue, +8–11% EBITDA) is achievable if ASPIRE lands and commercial volumes turn — but it would be the first year of genuine operating growth as a standalone company, and the burden of proof sits with management.

6. Financial Quality

Margins and returns: good absolute cash economics, mediocre returns on total capital. Amrize converts ~25% of revenue to adjusted EBITDA and generates real cash, but the return on invested capital — the number that matters for whether growth creates value — is only ~7.6% (ROIC.ai basis), roughly at or below a plausible 8–9% WACC. This is the defining financial fact. The cause is structural, not optical: the Building Materials core earns attractive ~29% segment margins, but the blended figure is dragged by (a) lower-return cement/ready-mix within Building Materials and (b) a Building Envelope roll-up bought at prices that loaded $9.0B of goodwill and $1.7B of other intangibles — $10.75B, or 44% of the $24.2B balance sheet. Tangible book is only ~$2.5B ($4.53/share). Contrast this with Vulcan/Martin Marietta, whose similar ~8% consolidated ROIC masks high-teens returns on the underlying rock; here the ~7.6% is closer to the true blended economics, more like post-AZEK James Hardie than like a pure-aggregates compounder. The ROE figure requires a warning: aggregators (and ROIC.ai) show a nonsensical ~261% “return on common equity” — an artifact of the near-zero restated carve-out equity base pre-spin; the real post-spin ROE is ~9% ($1.185B on $13.25B equity). Ignore the headline ROE.

Quality of earnings: clean, with a modest adjusted-vs-GAAP wedge to watch. The company reports “adjusted EBITDA” of ~$3.0B against a GAAP EBITDA of ~$2.81B — a ~$172M wedge (spin/separation $43M, acquisition-integration $64M, excess litigation ~$37M, restructuring $19M, impairments $15M) that is ~5.7% of adjusted EBITDA — modest and clean by industrial-adjustment standards, not aggressive, though it should be normalized before applying peer multiples. Most of it (spin, integration) is genuinely non-recurring. GAAP net income ($1.185B) is high-quality: cash conversion is strong (CFO $2.208B, ~1.9x net income), SBC is trivial (~$14M, unusual and favorable for a former-European-parent spin), and the effective tax rate (~21.8%) is normal. Two quality-of-earnings caveats temper this. First, Amrize disclosed a material weakness in internal control over financial reporting — “insufficient… U.S. GAAP technical accounting experience,” a legacy of carve-out financials derived from Holcim’s IFRS records; remediation is underway but the first §404 auditor attestation only arrives with the FY2026 10-K, so FY2025 GAAP figures warrant appropriate caution. Second, the $9.0B of goodwill (37% of assets), carried at Holcim-legacy basis, is a large latent impairment exposure whose disclosed trigger is precisely a construction downturn — no impairment has been taken, but a hard cyclical leg-down would test it. Netting these, a fair normalized run-rate is ~$3.0–3.1B EBITDA and ~$2.35–2.45 EPS (GAAP $2.14 plus non-recurring add-backs and the lower go-forward interest), before any volume recovery. Cash flow is the real strength. Levered free cash flow was ~$1.42B in 2025 (CFO $2.208B less $788M capex), a ~49% conversion of adjusted EBITDA that management flags as its through-cycle norm. FCF fell year-over-year (from $1.64B) on lower net income and higher growth capex — a deliberate reinvestment choice, not deterioration. On ~$28–30B of market cap that is a ~5% FCF yield, rising toward ~5.5% on 2026 estimates.

Balance sheet: genuinely de-risked post-spin — the clearest positive. Amrize entered independent life with a manageable structure: net debt of ~$3.35B, just ~1.1x adjusted EBITDA (management’s stated target is <1.5x; the covenant ceiling is a distant 3.75x), down sharply from the ~$8.6–9.5B of parent-allocated carve-out debt on the 2024 balance sheet. Interest coverage is ~6.8x, there is ~$1.9B of cash and ~$3.9B of committed liquidity (cash plus an undrawn $2.0B revolver; management’s “~$6B” headline grosses up revolver-backstopped commercial paper), and $5.3B of senior notes (well-laddered, blended ~4.9% coupon) term out the maturity wall. A normalization tailwind is embedded here: the $413M of reported 2025 net interest includes ~six months of pre-spin related-party interest — third-party-only interest was ~$216M, and the go-forward run-rate on $5.3B of notes is ~$260–290M, i.e., ~$120M+ (≈+$0.17/share after tax) below the reported figure. This low leverage is what funds the simultaneous capex ramp, bolt-on M&A and the new shareholder-return program without strain. Capital intensity is real but not extreme — capex ran ~6.7% of revenue in 2025 and D&A ($900M) modestly exceeds maintenance capex, consistent with a heavy-materials business that must continually replenish reserves and reline kilns.

Verdict: economics do not materially improve with scale — the roll-up added revenue and goodwill faster than returns. The business throws off strong, high-quality cash and sits on a de-risked balance sheet, but a ~7.6% ROIC on a $10.75B goodwill/intangible base is the honest financial signature of a company that paid up to assemble its second leg. Cash quality: high. Return quality: mediocre. Balance-sheet quality: strong.

7. Capital Allocation

Two eras: the Holcim-era roll-up (mixed-to-poor) and the standalone program (early, sensibly balanced).

The inherited record is the roofing acquisition wave — Firestone (~$3.4B), Malarkey, Duro-Last (~$1.29B) — executed by the same management team (Jenisch ran Holcim). The verdict is written in the returns: these deals doubled the company’s size but delivered a blended ~7.6% ROIC and $10.75B of goodwill/intangibles. Building Envelope’s ~22% segment margin sits below the ~27% Carlisle earns in commercial roofing and the ~32% Owens Corning earns in shingles — i.e., Amrize paid to enter roofing but did not buy best-in-class roofing economics. This is the core capital-allocation demerit: growth was purchased at prices that diluted returns, the Marathon “high returns attract capital, then mean-revert” warning made concrete.

The standalone program, announced with the February 2026 results, is more encouraging and better-directed:

• Reinvestment first, tilted to the moat. Capex rises to ~$900M in 2026 with growth capex more than doubling — and crucially, the M&A is now aggregates-led (PB Materials in West Texas, “a strong pipeline led by aggregates”). Buying rock rather than more roofing adds to the durable core; if sustained, this is a genuine improvement in allocation discipline.
• A maiden shareholder-return package: a $1B share-repurchase authorization plus a special one-time dividend of $0.44/share and an ordinary annual dividend of $0.44/share, paid out of Swiss capital-contribution reserves. Note the withholding nuance is more constrained than the market headline suggested: Swiss listed companies can shelter only up to ~50% of a distribution from the 35% Swiss withholding tax via capital-contribution reserves (of which Amrize had ~$2.16B available at year-end), and buybacks also draw that reserve down — so this is a partial, not a blanket, withholding advantage. At ~$50 the ordinary dividend is a modest ~0.9% yield; the $1B buyback is ~3.3% of market cap, meaningful but not aggressive.
• Incentive alignment / insider signal — genuinely bullish. SBC is trivially small (~$14M, unusually favorable for a former-European-parent spin), and — contrary to the “just initial grants” pattern typical of a fresh spin — there is a real cluster of open-market purchases (code P) in early 2026: Chairman/CEO Jan Jenisch bought ~47,000 shares (~$2.2M) at ~$45–50 across February and May 2026, joined by CFO Ian Johnston, the Chief Supply Chain Officer, the CTO and the CMO. C-suite buying into the post-February pullback at prices near today’s is a meaningful conviction signal and one of the cleaner positives in the file. On governance, the offsetting negative is that Jenisch holds the combined Chairman-and-CEO role (he is the board’s only non-independent director), and the founding-family legacy of Holcim persists in the shareholder register (Thomas Schmidheiny ~6.8%, via an active 13D). The comp structure benchmarks against exactly the right peer set (Vulcan, Martin Marietta, CRH, Owens Corning, Carlisle, Masco), with a 10x-salary CEO ownership guideline.

The tension to watch: management is doing four things at once — ramping growth capex, buying aggregates, buying back stock, and paying dividends — on ~$1.4–1.5B of annual FCF plus ~1.1x leverage headroom. That is affordable today. But the M&A “strong pipeline” is the risk: if Amrize resumes buying growth at sub-cost-of-capital returns (as the roofing roll-up did), the buyback-and-dividend discipline will not offset it. The single most important capital-allocation question for the next three years is whether the aggregates-led, returns-accretive M&A of PB Materials is the new template or a one-off.

Verdict: an inherited record that grew the company but diluted returns, now transitioning to a more balanced, better-targeted standalone program. Cautiously improved — but unproven, and the burden is on management to keep M&A accretive.

8. Changes and Headwinds — Last Two Years

The defining change is the spin-off itself (23 June 2025). Amrize went from a division of a Swiss global cement major to a standalone, US-listed, ~$28B-cap public company in a single tax-free dividend-in-kind distribution (one AMRZ share per Holcim share). With it came a purpose-built capital structure (~$8.6–9.5B of parent-allocated carve-out debt refinanced into $5.3B of senior notes — ~$6.3B gross including finance leases — leaving ~$3.3B net debt / ~1.1x EBITDA; ~$3.9B of committed liquidity from cash plus an undrawn $2.0B revolver), a full standalone management team under ex-Holcim CEO Jan Jenisch, Transition Services / Tax Matters / Separation agreements with Holcim (with attendant indemnity and Holcim-tax-liability exposures), and the operational overhead of becoming an independent SEC filer.

Operating headwinds of the last ~18 months:

• A soft residential cycle. Building Envelope revenue fell 2.2% in 2025 (and −11.8% in Q4) on weak residential roofing volumes, compounded by a mild 2025 storm season (fewer storms = less non-discretionary re-roof demand) and an $8M warranty-provision increase. Higher-for-longer rates and affordability are the culprits; management expects only a back-half-2026 recovery and is planning zero growth from new residential construction.
• Volume erosion in the core, masked by price. Cement and aggregates tons sold both fell in 2025 vs 2023, with pricing (aggregates especially) carrying revenue. A price-led, volume-down profile is defensible for aggregates but signals genuinely soft end-demand.
• Margin compression, partly one-time. Consolidated adjusted EBITDA margin fell from 27.2% (2024) to 25.5% (2025); both segments’ EBITDA declined in absolute dollars. The ~$181M organic EBITDA decline was driven partly by a one-time cement-network equipment outage (elevated manufacturing/distribution cost), higher standalone corporate costs (−$210M vs −$141M), and the lapping of 2024 land-sale gains — so a meaningful slice of the 2025 margin dip is non-structural, and outage recovery is a 2026 tailwind.
• Distributor consolidation. QXO’s acquisition of Beacon reshapes the roofing-distribution landscape into which Building Envelope sells ~70% of its volume — a slow-burn margin headwind (§4).

Offsetting positive changes: leverage cut to ~1.1x; the ASPIRE synergy program launched (first savings visible in Q4’25 Building Materials); a maiden shareholder-return package (§7); aggregates-led M&A restarted with PB Materials; and growth capex more than doubling into debottlenecking and greenfield projects. Net: the thesis is modestly strengthened structurally (de-levered, self-help underway, better-directed capital) but pressured cyclically (residential, volumes, margins).

9. Risk Analysis

Likelihood and impact are analyst judgments.

Catastrophic-loss risk is low. This is an asset-heavy, cash-generative, investment-grade-leverage business with irreplaceable reserves — not a balance-sheet or going-concern risk. The realistic bear outcome is dead-money mediocrity (a 7.6%-ROIC cyclical that never earns its multiple), not impairment or insolvency.

10. Valuation Discussion

At ~$50 the market caps Amrize at ~$28–30B of equity and ~$34.3B of enterprise value — ~12.2x trailing / ~10x forward adjusted EBITDA, ~2.9x EV/sales, ~18x EV/EBIT, ~24x trailing earnings, and a ~5% trailing FCF yield. On its own (short, ~1-year) history the AZI valuation-index percentiles read cheap on book/sales (P/B 8th, P/S 16th percentile) and mid on earnings (P/E 64th) — but with barely a year of trading data those percentiles carry little weight and should be treated as noise, not signal.

The correct comp frame is decisive, and it is not Vulcan/Martin Marietta. Those pure-aggregates names trade at 17.5–19x EV/EBITDA — a scarcity premium for permit-protected local-monopoly rock. Amrize’s Building Materials segment is integrated (cement + aggregates + ready-mix, the former Holcim NA business), which maps to the diversified/integrated heavy-materials band (CRH, Heidelberg, Eagle, Summit) at ~9–13x — a structural 6–8x discount to pure aggregates that our Vulcan and Martin Marietta work documents explicitly, and that Martin Marietta’s own exit from cement corroborates. On the building-products side, Amrize’s roofing leg belongs in the ~7.5–14x band (Owens Corning ~7.5x, Masco ~11x, James Hardie ~12.7x, Carlisle ~14x). Amrize’s blended 12.2x sits almost exactly where James Hardie trades — another levered, goodwill-diluted, roll-up-encumbered building-materials name — which feels about right.

Sum-of-the-parts sharpens it. Valuing the two segments on appropriate peer multiples (Building Materials segment adjusted EBITDA ~$2.5B; Building Envelope ~$0.7B):

*~553M shares; net debt ~$3.3B held constant (buyback/M&A roughly offset FCF).

Read the SOTP honestly. The entire spread between “fairly valued at $50” and “cheap by $15+” is a single question: how aggregates-rich is Building Materials, and are those aggregates being under-credited? The bull inputs are not fantasy — aggregates revenue ($4.67B) exceeds cement revenue ($4.39B), the reserve base is 8.2 billion tons, and aggregates pricing power is visibly intact (+6.1% in 2025). If a large slice of the $2.5B BM EBITDA is genuinely Vulcan-quality rock deserving 15x+, the market is under-crediting hidden value and the stock is worth $60–70+. But the bear inputs are equally real: cement earns higher margins within BM (so it contributes more EBITDA than its revenue share implies), cement carries the import/carbon discount, ready-mix is a no-moat commodity, and the ~7.6% consolidated ROIC argues the low return is structural rather than a Vulcan-style goodwill optical illusion. On balance the base case — BM as an integrated business worth ~13x, not a pure-aggregates 17x+ — puts intrinsic value modestly above the current price (~$60–67), but the realization of that value depends on the aggregates re-rate and ASPIRE execution the bears doubt.

Embedded expectations. At ~10x forward EBITDA and ~21x forward earnings, the market is pricing the 2026 guide (+4–6% revenue, +8–11% EBITDA) landing roughly as stated — but not pricing a durable re-rate toward pure-aggregates multiples, and not penalizing the stock for the 7.6% ROIC to a distressed level. In other words, consensus is underwriting “the guide is real, the self-help lands, but this stays a blended-materials multiple, not an aggregates multiple.” The upside case requires the market to re-credit the aggregates core; the downside case requires the guide to miss (residential stays broken, cement pricing disappoints, ASPIRE under-delivers). Both are live. No price target; the above frames the range of embedded outcomes.

11. Variant Perception

Consensus view: a solid, well-managed, de-levered spin-off of good North American building-materials assets, fairly valued at ~12x EBITDA, with a credible self-help story (ASPIRE) and secular tailwinds (data centers, infrastructure) — a “quality hold, buy the dips” name. Sell-side is clustered around $48–58 price targets (Truist Hold $48, Wells Fargo Overweight $58) — i.e., the Street sees it as roughly fairly valued with mild dispersion.

The strongest bull case: the market is applying a blended-materials multiple to a business whose Building Materials core is more aggregates-rich than it looks (aggregates revenue > cement, 8.2B-ton reserve base, +6.1% pricing power). As ASPIRE delivers 70bps+ of margin expansion, the data-center/infrastructure volume wave lands, and rate cuts revive commercial construction, EBITDA compounds high-single-digits and the market gradually re-credits the aggregates quality — a double-barreled earnings-growth-plus-re-rating story toward $65–75. The de-risked balance sheet and returns-accretive aggregates M&A (PB Materials) compound it. Jenisch has done this before (he built Holcim’s margins).

The strongest bear case: this is a ~7.6%-ROIC, no-organic-growth cyclical dressed as a compounder. Revenue has been flat for three years, volumes are falling, 2025 EBITDA and EPS both declined, and the entire forward story rests on synergies a doubled-by-acquisition company has never extracted plus a commercial/residential recovery that keeps slipping. The roofing roll-up permanently diluted returns and loaded $10.75B of goodwill; cement faces import and carbon headwinds; distributor consolidation squeezes Building Envelope. At ~24x trailing earnings the stock is too expensive for what it is, and the honest outcome is dead-money mediocrity — a round-trip that already happened once ($65 → $50) and can happen again toward the low-$40s.

The 3–5 assumptions that matter most:

1. ASPIRE margin delivery — does the 70bps-in-2026 / $250M-by-2028 self-help actually show up? (Falsifiable within 2–3 quarters of segment margins.)
2. Aggregates/cement pricing traction — does 2026 pricing come through as guided (cement LSD, aggregates MSD), or does management’s serial “nothing negative to report” mask softening? (Falsifiable in Q1–Q2’26 prints.)
3. Commercial recovery + data centers — does rate-cut-driven commercial volume (and the data-center build-out) actually inflect, or stay a narrative? (Falsifiable in volume growth by end-market.)
4. ROIC trajectory — does return on invested capital climb toward 9–10% (bull) or stall at ~7–8% (bear)?
5. M&A discipline — is PB Materials (aggregates, accretive) the new template, or does the “strong pipeline” resume diluting returns?

Factor-positioning read (subordinate to the thesis): the tape corroborates the bear’s “priced-for-execution” framing. Amrize is a high-beta (~1.32), market-factor-driven cyclical (FactorsToday base-model Market beta ~1.15, R² ~0.35) with negative alpha and a roughly flat first-year total return (+1.4%) at a negative Sharpe — it has swung with the market and underperformed it. The stock is not a momentum darling and not a falling knife; it is a range-bound, recently-derated name that spiked on a one-time capital-return catalyst and gave it all back. That is consistent with a market that has already priced the good news and is now waiting for proof — exactly the juncture at which execution, not narrative, sets the next move.

12. Fact vs. Interpretation

13. Open Questions

1. What is the aggregates-vs-cement EBITDA split within Building Materials? The entire bull/bear valuation gap turns on this and Amrize does not disclose it. (Aggregates revenue exceeds cement revenue, but cement earns higher margins — so the EBITDA split is genuinely ambiguous.)
2. Will ASPIRE deliver 70bps in 2026 and $250M by 2028? A doubled-by-acquisition company extracting procurement synergies for the first time — credible, but unproven at this team’s standalone execution.
3. Does the commercial/data-center recovery inflect in the numbers, or stay narrative? No quantified data-center exposure is disclosed; the thesis rests on management framing.
4. Is PB Materials the new M&A template (aggregates, accretive) or a one-off before the pipeline reverts to dilutive deals?
5. How much does cement carbon regulation actually cost, and can any of it be recovered? The 10-K says it “may not be able to recover” — an open, unquantified structural margin risk.
6. How real is the QXO/Beacon distributor-consolidation pressure on Building Envelope margins? (Interpretation, not disclosed — but a genuine multi-year question.)
7. When does the ICFR material weakness remediate, and does the first §404 attestation surface any restatement risk?

14. What Must Be True

For the bull case (intrinsic value $60–75+, a re-rating-plus-growth story):

• ASPIRE delivers visible, sustained Building Materials margin expansion (toward the mid-30s% segment EBITDA), proving the self-help is real.
• Aggregates/cement volumes inflect positive in 2026 as commercial (data centers, warehousing) and infrastructure demand lands, with pricing holding.
• ROIC climbs toward 9–10%+ as the growth capex and accretive aggregates M&A season, and the market re-credits the aggregates core toward a partial premium.
• Falsification test: two consecutive quarters of flat-or-down Building Materials segment margins and no volume inflection by 2H’26 falsify the “self-help + recovery” bull.

For the bear case (dead-money mediocrity, a round-trip toward the low-$40s):

• Residential roofing stays broken into 2027 and the commercial recovery keeps slipping; volumes remain soft.
• ASPIRE under-delivers or is competed away in price; aggregates/cement pricing traction disappoints (management’s serial “nothing negative to report” masks softening).
• ROIC stalls at ~7–8%, the M&A pipeline resumes diluting returns, and the market de-rates a 7.6%-ROIC, no-organic-growth cyclical trading at ~24x trailing earnings.
• Falsification test: ASPIRE clearly delivering 70bps+ and ROIC rising through 9% and positive organic volume growth would falsify the bear.

The synthesis: the falsifiable evidence arrives fast — within two to three quarterly prints we will see whether ASPIRE margins and commercial/data-center volumes are real. That makes AMRZ a “prove-it” name where the burden of proof, at ~24x trailing / ~10x forward EBITDA, sits squarely on management. The balance sheet, the aggregates moat, and the genuine insider buying are the floor under the story; the flat organic history, the 7.6% ROIC, and the goodwill are the ceiling on it.

15. Source Appendix

Primary sources (SEC filings, mirrored locally to output/AMRZ/sources/): Amrize Ltd FY2025 Form 10-K (filed 2026-02-18; income statement, balance sheet, cash flow, segment data, aggregates reserves, debt note, risk factors, MD&A); Form 10 registration (10-12B/A); three Form 10-Qs (Q2/Q3’25, Q1’26); 15 Form 8-Ks (spin completion 23-Jun-2025, quarterly earnings, debt exchange); DEF 14A proxy (2026-03-12; governance, compensation, 5%-holders); Form 3/4 insider corpus (~70 Form 4 / 26 Form 3, incl. the 2026 open-market purchase cluster). Company communications: Q4/FY2025 earnings call transcript (2026-02-18, Jenisch/Johnston). Quantitative cross-checks (third-party, reconciled to filings): ROIC.ai MCP (statements, ratios, enterprise value, valuation multiples, transcripts), AZI (valuation-index own-history percentiles; daily price/OHLCV CSV), FactorsToday (factor loadings, leaderboard, stock-info). Peer/industry cross-read: prior initiation reports on CRH, Martin Marietta (MLM), Vulcan (VMC), Owens Corning (OC), Carlisle (CSL), James Hardie (JHX), Masco (MAS), Simpson (SSD). Internal context ``: “Holcim AG Investment Analysis” (parent pre-spin segment economics). Full itemized appendix accompanies this memo as AMRZ_source_appendix.md.

This is an independent analyst’s article for general information only and is not investment advice. No buy/sell recommendation and no price target appears anywhere in the body; the sole opinion is the clearly-fenced author’s-view block at the top.

APPENDIX A — Standard Diligence Questionnaire

Amrize Ltd (NYSE: AMRZ) — Standard Diligence Questionnaire

Supplemental to the report. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant one, visible across the Q4’25 call, is whether Building Materials pricing (especially cement) actually holds in 2026 given peers’ weaker traction — analysts pressed Jenisch repeatedly and got “nothing negative to report.” Others: how large and durable is the data-center demand pull; whether ASPIRE synergies are real or a rebadging of normal cost control; how QXO’s consolidation of roofing distribution (Beacon) reshapes Building Envelope economics; and the mechanics of the Swiss capital-contribution-reserve dividend (withholding treatment). The under-asked question is the one that matters most for value: the aggregates-vs-cement EBITDA split inside Building Materials, which the company does not disclose and which decides whether 12x EBITDA is cheap or fair.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: mid-to-low. 2025 adjusted EBITDA ($3.0B) fell from 2024 ($3.18B); residential roofing is in a genuine downcycle, cement/aggregates volumes are below 2023, and a one-time cement-network outage depressed margins. This is not a peak — but nor is it a washed-out trough, since aggregates pricing is still rising and infrastructure demand is firm. Driven by external environment or internal actions? Both: the volume softness is external (rates, residential), while the margin path from here is meant to be internal (ASPIRE self-help, outage recovery, interest normalization). How stable are revenues? More stable than a pure new-construction cyclical — 43% of revenue is repair-and-remodel, and re-roofing/infrastructure demand is relatively non-discretionary — but still cyclical, with a high market beta (~1.32). Outlook for products/services? Structurally fine: cement/aggregates are irreplaceable inputs to construction; roofing replacement demand grows with the aging installed base. How big is the market? Management cites a ~$200B addressable North American market; growing with infrastructure spend, data-center construction and the housing shortage — domestic (US + Canada only).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Mixed — aggregates and commercial roofing are consolidating oligopolies (favorable); ready-mix is fragmented and low-barrier; cement faces persistent coastal import competition. How profitable is the business (ROIC, ROE)? Mediocre on capital: blended ROIC ~7.6%, real ROE ~9% (the ~261% aggregator figure is a carve-out-equity artifact — ignore it). Segment EBITDA margins are healthy (BM 29%, BE 22%), but the goodwill-heavy base drags returns. How profitable is the industry? Aggregates is among the best in industrials (local monopolies, high-teens core returns); cement and ready-mix materially lower. Barriers to entry? High for aggregates/cement (geology, permitting, freight, capital); low for ready-mix (the 10-K says so). Can the business be easily understood? Yes — it sells rock, cement, concrete and roofing. Undermined by foreign low-cost labor? No — freight-bound, domestic; the relevant import threat is cement clinker on the coasts, not labor. Do brands matter? Modestly — in Building Envelope (Elevate, Duro-Last, Malarkey warrantied systems create spec-in/switching costs); barely in Building Materials (rock is rock). Nature of competition? Local/regional pricing discipline in aggregates/cement; branded oligopoly in roofing; commodity in ready-mix. Switching costs? Real in warrantied roofing systems (contractor certification), negligible in materials.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: yes — the 8.2-billion-ton aggregates reserve base and irreplaceable, un-permittable quarry positions are carried at historical/legacy cost, likely well below economic value (the classic hidden-asset case in aggregates). Off-balance-sheet liabilities? Operating leases, multi-decade (5–30yr) roofing warranties (“not insurable”), pension (~$229M), and asset-retirement/reclamation obligations on quarries; carbon-compliance costs are a future liability not yet quantified. How conservative is the accounting? Adjustments to EBITDA are modest (~5.7%) and SBC trivial — favorable — but there is a disclosed material weakness in ICFR (U.S. GAAP staffing) and the financials are carve-out-derived from Holcim IFRS, so first-year GAAP figures warrant caution. How CapEx-hungry? Moderately — capex ~6.7% of revenue, rising to ~$900M (2026) as growth capex more than doubles; D&A (~$900M) currently exceeds capex, though the business must perpetually replenish reserves and reline kilns.

Capital Allocation & Management

How much FCF, and how used? ~$1.4–1.5B levered FCF (~49% of adjusted EBITDA); used for growth capex, aggregates M&A (PB Materials), a $1B buyback and dividends. Philosophy? Newly articulated post-spin: reinvest first (tilted to aggregates), then return cash — a sensible, balanced framework, if unproven. Significant acquisitions? Holcim-era roofing roll-up (Firestone ~$3.4B, Malarkey, Duro-Last ~$1.29B) that diluted returns; now aggregates-led bolt-ons (PB Materials ~$180M revenue, accretive). Buying back shares? Yes — maiden $1B authorization (~3.3% of cap). Issuing shares to insiders? No — SBC is trivial (~$14M); dilution is negligible. Compensation of directors/management? Benchmarked to the right peer set (VMC, MLM, CRH, OC, CSL, Masco); CEO ownership guideline 10x salary; standard base + annual + LTI (RSU/PSU). Motivations of management? Interpretation: aligned and confident — Chairman/CEO Jenisch and five other officers made open-market purchases (~$45–50, early 2026), Jenisch ~$2.2M. Governance demerit: combined Chairman-and-CEO.

Valuation & Market Data

ADR, MLP, or K-1 issuer? None — it is ordinary shares of a Swiss company listed directly on the NYSE (and SIX); not an ADR, not a partnership, no K-1. Note the Swiss 35% dividend withholding, only partly (≤50%) shelterable via capital-contribution reserves, and USD/CHF FX exposure on the share price. Dividend policy? New: ordinary $0.44/share annual (~0.9% yield) plus a one-time special $0.44. How profitable? ~10% net margin, ~25% EBITDA margin, ~7.6% ROIC. Net income diverging from cash from operations? Favorably — CFO ($2.21B) is ~1.9x net income ($1.19B); cash conversion is a strength, not a red flag.

Risks & Downside

What would cause the stock to decline? A construction downturn (volume + price together); residential roofing staying weak; ASPIRE under-delivering; cement pricing/carbon disappointing; a dilutive return to roofing M&A; a goodwill impairment; or simple multiple compression on a 7.6%-ROIC cyclical (which already happened once, $65→$50). Catastrophic-loss risk? Low — investment-grade leverage (~1.1x net), irreplaceable assets, strong cash generation; this is a dead-money risk, not an impairment/insolvency risk. Chance of a total loss? Negligible on any reasonable horizon.

Recent News & Events

Has the business environment changed recently? Yes — the spin (Jun 2025) is the defining change; plus a soft residential cycle, QXO’s consolidation of roofing distribution, and sell-side cooling (Truist → Hold $48; Wells Fargo trim to $58, both July 2026). Significant acquisitions? PB Materials (West Texas aggregates, closing Q1’26); OX Engineered Products (2025). Change in accounting policies? The move from Holcim IFRS carve-out to standalone U.S. GAAP (with the associated ICFR material weakness). Recent changes — new markets, facilities, management? New standalone board and C-suite; growth projects (Ste. Genevieve cement expansion, Oklahoma greenfield quarry, new Malarkey shingle plant); ASPIRE program launched Q2’25.

APPENDIX B — Source Appendix

Amrize Ltd (NYSE: AMRZ) — Source Appendix

Accessed 2026-07-18 unless noted. Primary sources first; third-party aggregated quantitative sources reconciled to filings; internal sources labeled ``.

Primary — SEC filings (CIK 0002035989; mirrored locally to output/AMRZ/sources/)

1. FY2025 Form 10-K (period ended 31-Dec-2025; filed 18-Feb-2026) — income statement, balance sheet, cash flow; segment note (Building Materials / Building Envelope revenue and adjusted EBITDA); Item 1 Business (brands, competition, customers); Item 2 Properties (18 cement plants, 467 aggregates operations, 8,220M-ton reserves, realized prices); Item 1A Risk Factors; MD&A (2025-vs-2024 bridge, one-time items, interest); Note 10 Debt (senior-note stack, maturities, $5,267M principal); material-weakness disclosure; Swiss-withholding risk factor.
2. Form 10 Registration Statement (10-12B and 10-12B/A) (filed 28-Feb-2025 / amended 07-May-2025) — spin structure, carve-out financials, separation agreements.
3. Form 10-Q filings — Q2 2025 (06-Aug-2025), Q3 2025 (29-Oct-2025), Q1 2026 (07-May-2026).
4. Form 8-K corpus (15 filings) — spin completion (23-Jun-2025), debt-exchange results (18-Jun-2025), quarterly earnings releases (06-Aug-2025 Q2, 28-Oct-2025 Q3, 17-Feb-2026 Q4/FY25, 21-Apr-2026 Q1’26), other material events.
5. DEF 14A proxy statement (filed 12-Mar-2026) — board (9→11, combined Chair/CEO Jenisch), executive compensation and peer group, 5%-holders (Schmidheiny 6.8%, UBS 6.9%, Vanguard 5.4%; Holcim 0%), share-ownership guidelines, 2025 Omnibus Plan.
6. Form 3 / Form 4 insider corpus (~26 Form 3 / ~70 Form 4) — post-spin initial ownership statements and the Feb/May-2026 open-market purchase cluster (Jenisch ~47,000 sh / ~$2.2M; CFO Johnston; CSCO Gross; CTO Brouwer; CMO Forrest).
7. Schedule 13D/13G — Thomas Schmidheiny 13D (27-Jun-2025); UBS, Vanguard 13G.

Primary — company communications

8. Amrize Q4 & FY2025 earnings call transcript (18-Feb-2026) — Jan Jenisch (Chairman/CEO), Ian Johnston (CFO): FY2025 results, 2026 guidance (+4–6% revenue, +8–11% adjusted EBITDA), ASPIRE synergy targets (70bps 2026, $250M by 2028), PB Materials acquisition, capital-return announcement ($1B buyback, special + ordinary $0.44 dividend), data-center/commercial demand commentary, Ste. Genevieve expansion. (Source: ROIC.ai get_earnings_call_transcript, Q4 2025.)
9. Amrize Investor Relations — investors.amrize.com (earnings releases, slide presentations, medium-term targets).

Quantitative cross-checks (third-party aggregated; reconciled to filings)

10. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability ratios (ROIC, ROE, margins), credit ratios, per-share data, enterprise value, valuation multiples (5-year annual); earnings-call transcripts. Caveat: reported ROE (~261%) is a carve-out-equity artifact — real ROE ~9%.
11. AZI (azitrading.com) — fundamentals valuation_index own-history percentiles (composite 29th; P/E 64th, P/B 8th, P/S 16th; ~1yr history — low weight); daily price/OHLCV CSV (since 23-Jun-2025 spin); news feed (Truist/Wells Fargo rating actions, Jul-2026).
12. FactorsToday (factorstoday.com/api) — /stock-loadings (Market beta ~1.15 base / ~1.32 realized, R² ~0.35), /leaderboard (y1 return +1.4%, negative Sharpe), /stock-info (beta, alpha, relative strength).

Peer / competitor data (prior initiation reports; output/)

13. CRH plc (CRH_2026-06-14_full_report.md) — the key structural analog: blended NA aggregates/cement/building-products at ~11.8x EV/EBITDA, ROIC ~10–12%, discount to VMC/MLM.
14. Martin Marietta (MLM_2026-06-21), Vulcan (VMC_2026-06-20) — pure-aggregates comps (17.5–19x EV/EBITDA); cement-exit read (MLM Quikrete swap).
15. Owens Corning (OC_2026-07-04), Carlisle (CSL_2026-07-04), James Hardie (JHX_2026-07-11), Masco (MAS_2026-07-03), Simpson (SSD_2026-06-21) — building-products comps for Building Envelope and blended-multiple context.

Industry / regulatory

16. US aggregates transport economics and permitting; US cement import dynamics and CO₂/carbon regulation (EPA/CEPA; Canada carbon tax); commercial single-ply roofing oligopoly structure; residential shingle market shares and storm cyclicality — synthesized from the peer reports above and the FY2025 10-K’s own Item 1/1A disclosures.

Additional industry context

17. Holcim Ltd public FY2024 annual report and segment disclosures — parent pre-spin segment economics (cement, aggregates, ready-mix, solutions & products margins) and the strategic rationale for the North American separation.